Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples